Polycystic Kidney Disease Market to Grow with a CAGR of 6.89% through 2028
Rising advancements in genetic research leading to
targeted therapies are expected to drive the Global Polycystic Kidney Disease Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “Polycystic
Kidney Disease Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Polycystic Kidney Disease Market
stood at USD 488.23 million in 2022 and is anticipated to grow with a CAGR of 6.89%
in the forecast period, 2024-2028. The global Polycystic Kidney Disease market
has been experiencing substantial growth, driven by a confluence of key market
drivers. These drivers include the increasing prevalence of PKD, advancements
in genetic research, the development of targeted therapies, collaborative
efforts among stakeholders, and increasing patient advocacy and awareness. One of the primary drivers of the global PKD market is
the increasing prevalence of the disease. PKD affects millions of people
worldwide, making it one of the most common genetic disorders. As more
individuals are diagnosed with PKD, there is a growing demand for effective
treatments and therapies to manage the disease. This rising patient population
has attracted the attention of pharmaceutical companies and research
institutions, leading to increased investment in PKD research and drug
development. The genetic nature of PKD has opened up new avenues for research
and treatment development. Advances in genetic research have enabled scientists
to identify specific genetic mutations responsible for PKD. This knowledge has
paved the way for precision medicine approaches, where treatments can be
tailored to target the underlying genetic causes of the disease. The ability to
develop therapies that directly address the genetic basis of PKD represents a
significant breakthrough in the field.
The development of targeted therapies is a key driver
of the PKD market. These therapies aim to slow the progression of cyst growth,
delay the onset of kidney failure, and improve the quality of life for PKD
patients. Targeted therapies can include small molecule drugs, gene therapies,
and other innovative treatment modalities. As research continues to uncover the
molecular mechanisms of PKD, the potential for developing more effective
targeted therapies grows, driving market growth. Collaboration has been
instrumental in advancing PKD research and treatment development.
Pharmaceutical companies, academic institutions, and patient advocacy groups
have formed partnerships to pool resources, share knowledge, and accelerate
progress. These collaborations have facilitated the funding of clinical trials,
the discovery of potential drug candidates, and the establishment of patient
registries. Such collaborative efforts have been pivotal in shaping the PKD
market. Patient advocacy groups and organizations have played a crucial role in
raising awareness about PKD and advocating for research and treatment advancements.
These groups provide support to patients and their families while also
mobilizing resources for research funding. Additionally, their advocacy efforts
have contributed to increased public and governmental awareness of PKD, leading
to greater funding and research initiatives.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Polycystic
Kidney Disease Market.”
Improvements in diagnostic techniques have enhanced
the early detection and monitoring of PKD. Non-invasive imaging technologies,
such as magnetic resonance imaging (MRI) and ultrasound, allow for the
visualization of kidney cysts and their growth patterns. Early diagnosis
enables healthcare providers to initiate treatment strategies at an earlier
stage of the disease, potentially slowing its progression and improving patient
outcomes. Biomarkers are substances that can be measured in the body and
indicate the presence or progression of a disease. In the case of PKD,
biomarker identification has the potential to revolutionize diagnosis and
monitoring. Researchers are actively searching for reliable biomarkers
associated with PKD, which could aid in early detection and provide valuable
insights into disease progression.
The Global Polycystic Kidney Disease Market is
segmented into Type, Treatment Type, End User, regional distribution, and
company.
Based on the Type, the Autosomal dominant polycystic
kidney disease (ADPKD) segment emerged as the dominant segment in the global
market for Global Polycystic Kidney Disease Market in 2022. ADPKD affects a
larger number of individuals worldwide due to its higher prevalence. This
larger patient population drives increased demand for diagnostic tools,
treatments, and therapies related to ADPKD, thereby boosting the global PKD
market. Pharmaceutical companies and research institutions have predominantly
focused their efforts on ADPKD due to its higher prevalence. The larger patient
pool offers a more significant market potential for drug development, resulting
in more extensive investments in ADPKD-related research. Clinical trials for
PKD treatments often primarily involve ADPKD patients due to their larger
numbers. Successful clinical trials for ADPKD treatments can have a more
immediate impact on the market, leading to the development of targeted
therapies and treatment options.
Based on the Treatment, the Diagnosis segment emerged
as the dominant player in the global market for Global Polycystic Kidney
Disease Market in 2022. Early diagnosis
is crucial in managing PKD effectively. Diagnostic tools and techniques, such
as imaging studies and genetic testing,
enable the early detection of cyst formation in the kidneys. This allows
healthcare providers to initiate treatment strategies at a stage when interventions
are most likely to be effective, potentially slowing the progression of the
disease and improving patient outcomes. As a result, there is a high demand for
advanced and accurate diagnostic methods in the PKD market. Diagnostic advancements are instrumental in supporting
PKD research and clinical trials. Validated biomarkers and precise diagnostic
tools are essential for identifying suitable patient populations, monitoring
disease progression, and assessing treatment efficacy in clinical studies. The
availability of reliable diagnostics is critical for conducting successful
research and drug development efforts.
Based on the By End User, the Hospitals & Clinics segment
emerged as the dominant player in the global market for Global Polycystic
Kidney Disease Market in 2022
Patients
with PKD often require specialized care from nephrologists, urologists, and
other healthcare professionals with expertise in managing kidney disorders.
Hospitals and clinics are well-equipped to provide such specialized care,
including access to diagnostic imaging, laboratory services, and surgical
facilities when needed. Accurate and early diagnosis of PKD is critical for
effective disease management. Hospitals and clinics offer a wide range of
diagnostic services, including ultrasound, magnetic resonance imaging (MRI),
and genetic testing, which are essential for identifying and monitoring PKD.
North America emerged as the dominant player in the
global Polycystic Kidney Disease Market
in 2022, holding the largest market share. North America boasts a highly
developed healthcare infrastructure with state-of-the-art medical facilities,
renowned research institutions, and access to cutting-edge diagnostic tools and
therapies. This advanced healthcare ecosystem enables early detection, accurate
diagnosis, and the effective management of PKD, making it a frontrunner in the
market.
Major companies operating in Global Polycystic
Kidney Disease Market are:
- Otsuka Pharmaceuticals
- Camber Pharmaceuticals
- Apotex Corp
- Ascend Laboratories
- Par Pharmaceuticals
- Teva Pharmaceutical Industries
- Merck KGA
- Accord Healthcare
- Pfizer Inc.
- PD-Rx Pharmaceuticals, Inc
Download
Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global
Polycystic Kidney Disease (PKD) market is poised for substantial growth in the
coming years, driven by several key factors. First, advancements in genetic
research have deepened our understanding of PKD's genetic underpinnings,
leading to the development of targeted therapies and precision medicine
approaches. This progress holds the promise of more effective treatments and
improved patient outcomes. Second, the identification of biomarkers for early
diagnosis and disease monitoring is revolutionizing PKD care, enabling timely
interventions and personalized treatment plans. Third, the growing awareness of
PKD, bolstered by patient advocacy groups and healthcare professionals, is
leading to earlier diagnosis and heightened demand for PKD-related services.
Lastly, collaborations between research institutions, pharmaceutical companies,
and patient advocacy groups are fostering research and innovation in the field.”
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“Polycystic Kidney Disease Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Type (Autosomal dominant
polycystic kidney disease (ADPKD), Autosomal recessive polycystic kidney
disease (ARPKD), Others), By Treatment Type (Diagnosis, Drug/Therapy), By End
User (Hospitals & Clinics, Ambulatory Care Centers, Others) By Region and
Competition”, has evaluated the future growth potential of Global Polycystic Kidney
Disease Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Polycystic Kidney
Disease Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com